title: Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
abstract: Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders. We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone. Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause. The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone. This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.
authors: Department of Psychiatry, Gaziantep University Faculty of Medicine, Gaziantep, Turkey.
authors: Murat Eren
authors: ME
authors: Ozen
authors: Mehmet
authors: M
authors: Yumru
authors: Haluk A
authors: HA
authors: Savas
authors: Neslihan
authors: N
authors: Cansel
authors: Hasan
authors: H
authors: Herken
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001712:Biperiden / Q000008:administration & dosage; D003937:Diagnosis, Differential; D003975:Diazepam / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy / Q000209:etiology*; D009460:Neurologic Examination / Q000187:drug effects; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; D001712:Biperiden; C092292:ziprasidone; D003975:Diazepam